Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective ‘true-to-life’ study
Therapeutic Advances in Psychopharmacology · 2023-01 · 13
DOI: 10.1177/20451253221135463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 16.02.2023. Verfasst von Antonio Augusto Schmitt Junior und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Depression
Abstract (Originalsprache)
Background
There is increasing evidence of the association between chronic low-grade inflammation and severe mental illness (SMI). The objective of our study was to assess serum cytokine levels (SCLs) at admission and discharge in a true-to-life-setting population of inpatients with major depression (MD), bipolar disorder (BD), and schizophrenia (Sz), as well as of healthy controls.
Methods
We considered MD, BD, and Sz to be SMIs. We evaluated 206 inpatients [MD, N = 92; BD, N = 26; mania (Ma), N = 44; Sz, N = 44). Generalized estimating equations were used to analyze variations in SCL [interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin (IL)-2, IL-4, IL-6, IL-10, and IL-17] at hospital admission and discharge. Results of 100 healthy controls were compared with those of SMI patients at both time points. We evaluated patients’ improvement during in-hospital treatment in terms of general psychiatric symptoms, global clinical impression, functionality, and manic and depressive symptoms with validated scales.
Results
In all, 68.9% of patients completed the study. Overall, SMI inpatients had higher SCL when compared with controls regardless of diagnosis. There was a significant decrease in Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression–Severity Scale (CGI-S) scores, and an increase in Global Assessment of Functioning (GAF) scores for all disorders evaluated ( p < 0.001), as well as a significant decrease in HDRS-17 scores among MD inpatients ( p < 0.001) and in YMRS scores among Ma inpatients ( p < 0.001). IL-2 and IL-6 levels decreased significantly between admission and discharge only among MD inpatients ( p = 0.002 and p = 0.03, respectively). We found no further statistically significant changes in SCL among the remaining disorders (BD, Ma, and Sz). There was no significant decrease in IFN-γ ( p = 0.64), TNF-α ( p = 0.87), IL-4 ( p = 0.21), IL-10 ( p = 0.88), and IL-17 ( p = 0.71) levels in any of the evaluated diagnoses.
Conclusion
MD inpatients had a decrease in IL-2 and IL-6 levels during hospitalization, which was accompanied by clinical improvement. No associations were found for the remaining SMIs (BD, Ma, and Sz).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
- Center for Clinical Research, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.
- Graduate Program in Psychiatry and Behavioral Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Innovations and Interventions for Quality of Life (I-QoL), Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Postgraduate Programin Medical Sciences: Psychiatry, Avenue Ramiro Barcellos, 2…
- Innovations and Interventions for Quality of Life (I-QoL), Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
ORCID-Profile: Antonio Augusto Schmitt Junior, Lucas Primo de Carvalho Alves
Zitieren
APA
Schmitt Junior, A. A., Primo de Carvalho Alves, L., Padilha, B. L., & da Rocha, N. S. (2023). Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective ‘true-to-life’ study. Therapeutic Advances in Psychopharmacology, 13. https://doi.org/10.1177/20451253221135463
Vancouver
Schmitt Junior AA, Primo de Carvalho Alves L, Padilha BL, da Rocha NS. Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective ‘true-to-life’ study. Therapeutic Advances in Psychopharmacology. 2023;13. doi:10.1177/20451253221135463
BibTeX
@article{SchmittJunior2023,
author = {Schmitt Junior, Antonio Augusto and Primo de Carvalho Alves, Lucas and Padilha, Barbara Larissa and da Rocha, Neusa Sica},
title = {Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective ‘true-to-life’ study},
journal = {Therapeutic Advances in Psychopharmacology},
year = {2023},
volume = {13},
doi = {10.1177/20451253221135463}
}
EUVIMED